Key Proteo
Key Proteo develops innovative newborn screening technology for early genetic disease detection, improving patient life quality.
Founded
2019Key Proteo develops innovative newborn screening technology for early genetic disease detection, improving patient life quality.
keyproteo.comCrawled Oct 15, 2026
Key Proteo's Immuno-SRM proteomics-based platform is intended to enable early intervention.
Key Proteo Co-Founder and CEO Dr. Sihoun Hahn, MD, PhD, presented at the Wilson Aarhus 2026 Symposium — widely regarded as the world's leading scientific conference dedicated to Wilson Disease. His presentation updated the global research community on an evidence base that has grown substantially si
Key Proteo received CLIA certification authorizing its laboratory to perform diagnostic testing on human specimens.
Key Proteo announced that abstracts presenting its ATP7B proteomic testing data were accepted at EASL 2026, the annual congress of the European Association for the Study of the Liver.
Wilson Disease is notoriously difficult to diagnose with certainty. Genetic testing identifies ATP7B variants in the majority of cases, but a meaningful proportion of patients receive an indeterminate result, leaving clinicians and families without a clear path forward. Two new publications demonstr
The company is a proteomic diagnostics company that aims to expand newborn screening through early identification of treatable rare genetic conditions.
Key Proteo aims to expand newborn screening through early identification of treatable genetic conditions.
The company aims to save lives and reduce disease burden for people affected by rare treatable genetic disorders through early screening. Its proteomic technology supports early intervention, starting with newborns.